Company patents
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. demonstrates a highly concentrated patent strategy, with 85.4% of its portfolio in Therapeutic Activity and 78.0% in Heterocyclic Compounds, both showing significant growth in 2025 (200.0% and 112.5% YoY respectively), indicating a strong and recent push in core drug discovery, despite a sharp decline so far in 2026. The rapid decline in Pharmaceutical Preparations (down 100.0% YoY so far in 2026) suggests a shifting priority away from formulation-specific innovations.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
41 US filings (since 2023) · 4 categories · 7 themes
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Patents
Showing 1-1 of 1
API Solid Form Engineering